Medication info
Olpro Tablet 20/5 mg

Olpro Tablet 20/5 mg

Prescription medicationTabletOral
Ingredient · strength
Olmesartan Medoxomil›20mg / 1 tabletRosuvastatin Calcium›5.2mg / 1 tablet
Manufacturer / importer
Hana Pharmaceutical Co., Ltd.
Appearance
White or light yellow, round film-coated tablets
Packaging
30 tablets/box [(10 tablets/Alu-Alu)×3]
Approval status
Active

MFDS item code 202003963 · Approved 2020.05.28 · Insurance code 657807370

Summary

Main use
Treatment of hypertension, improvement of dyslipidemia, inhibition of atherosclerotic progression and cardiovascular disease risk
Who takes it
Adults · Children
Adult dose
This medicine is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, olmesartan medoxomil and rosuvastatin. ◆ Olmesartan medoxomil 1. Adults The recommended initial dose is 10mg once daily, regardless of meals. If blood pressure is not adequately controlled at this dose, increase the dose to 20mg once daily. If additional blood pressure reduction is required, the dose may be increased to a maximum of 40mg once daily. The blood pressure-lowering effect occurs within 2 weeks after starting treatment and reaches its maximum effect at approximately 8 weeks. If blood pressure is not controlled with this medicine alone, it may be administered in combination with a thiazide diuretic, such as hydrochlorothiazide. To improve adherence, it is recommended that the medicine be taken at the same time each day, if possible (e.g., in the morning). For patients who may have reduced effective circulating blood volume (e.g., patients taking diuretics, particularly those with renal impairment), it is recommended to initiate treatment at a lower dose while monitoring their condition closely. 2. Older adults No dose adjustment is necessary when this medicine is administered to older adults aged 65 years or older. No overall differences in efficacy or safety were observed between older and younger patients; however, the possibility of a more sensitive response in some older adults cannot be ruled out. 3. Patients with renal impairment The maximum dose for patients with mild or moderate renal impairment (creatinine clearance 30-60mL/min) is 20mg once daily. 4. Patients with hepatic impairment No dose adjustment is necessary for patients with mild hepatic impairment. The recommended initial dose for patients with moderate hepatic impairment is 10mg once daily, which may be increased to a maximum of 20mg daily. Use of this medicine is not recommended in patients with severe hepatic impairment because there is no experience with its use in these patients. ◆ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5mg once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to the maintenance dose. The maintenance dose is 10mg once daily, which provides control in most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and the patient's response; the dose may be increased to a maximum of 20mg daily. 2. Older adults No dose adjustment is necessary. 3. Patients with renal impairment No dose adjustment is necessary for patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution should be exercised when administering this medicine at a dose of 20mg to patients with moderate renal impairment. 4. Patients with hepatic impairment Although no increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score above 9. Do not administer this medicine to patients with active liver disease. 5. Race Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5mg. Administration of a 40mg dose is contraindicated. 6. Patients predisposed to myopathy The recommended initial dose for patients predisposed to myopathy is 5mg. Administration of a 40mg dose of this medicine is contraindicated in some of these patients. Patients taking olmesartan medoxomil and rosuvastatin concomitantly may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience of administration.
Child dose
The safety and efficacy in children under 18 years of age have not been established.

Ingredients

Manufacturer
Hana Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of hypertension, improvement of dyslipidemia, inhibition of atherosclerotic progression and cardiovascular disease risk

  • Essential hypertension
  • primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed dyslipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
  • primary dysbetalipoproteinemia
  • increased high-sensitivity C-reactive protein
  • hypertension
  • low HDL cholesterol
  • smoking
  • family history of early coronary heart disease
View approved original text

This medication is used for patients who require a combination of olmesartan medoxomil and rosuvastatin. Olmesartan medoxomil is primarily used to treat essential hypertension. Rosuvastatin helps with hypercholesterolemia and various types of dyslipidemia that cannot be managed through diet and exercise. Additionally, it lowers cholesterol levels in patients with hypercholesterolemia, delaying the progression of atherosclerosis and reducing the risk of cardiovascular diseases. It is particularly used in patients over 50 years old for men and over 60 years old for women who have cardiovascular risk factors, reducing the risk of stroke, myocardial infarction, and vascular revascularization procedures. Therefore, this medication improves cardiovascular health by managing blood pressure and cholesterol together.

How to take

Adult dose

This medicine is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, olmesartan medoxomil and rosuvastatin. ◆ Olmesartan medoxomil 1. Adults The recommended initial dose is 10mg once daily, regardless of meals. If blood pressure is not adequately controlled at this dose, increase the dose to 20mg once daily. If additional blood pressure reduction is required, the dose may be increased to a maximum of 40mg once daily. The blood pressure-lowering effect occurs within 2 weeks after starting treatment and reaches its maximum effect at approximately 8 weeks. If blood pressure is not controlled with this medicine alone, it may be administered in combination with a thiazide diuretic, such as hydrochlorothiazide. To improve adherence, it is recommended that the medicine be taken at the same time each day, if possible (e.g., in the morning). For patients who may have reduced effective circulating blood volume (e.g., patients taking diuretics, particularly those with renal impairment), it is recommended to initiate treatment at a lower dose while monitoring their condition closely. 2. Older adults No dose adjustment is necessary when this medicine is administered to older adults aged 65 years or older. No overall differences in efficacy or safety were observed between older and younger patients; however, the possibility of a more sensitive response in some older adults cannot be ruled out. 3. Patients with renal impairment The maximum dose for patients with mild or moderate renal impairment (creatinine clearance 30-60mL/min) is 20mg once daily. 4. Patients with hepatic impairment No dose adjustment is necessary for patients with mild hepatic impairment. The recommended initial dose for patients with moderate hepatic impairment is 10mg once daily, which may be increased to a maximum of 20mg daily. Use of this medicine is not recommended in patients with severe hepatic impairment because there is no experience with its use in these patients. ◆ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5mg once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to the maintenance dose. The maintenance dose is 10mg once daily, which provides control in most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and the patient's response; the dose may be increased to a maximum of 20mg daily. 2. Older adults No dose adjustment is necessary. 3. Patients with renal impairment No dose adjustment is necessary for patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution should be exercised when administering this medicine at a dose of 20mg to patients with moderate renal impairment. 4. Patients with hepatic impairment Although no increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score above 9. Do not administer this medicine to patients with active liver disease. 5. Race Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5mg. Administration of a 40mg dose is contraindicated. 6. Patients predisposed to myopathy The recommended initial dose for patients predisposed to myopathy is 5mg. Administration of a 40mg dose of this medicine is contraindicated in some of these patients. Patients taking olmesartan medoxomil and rosuvastatin concomitantly may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience of administration.

Child dose

The safety and efficacy in children under 18 years of age have not been established.

Precautions

This medication can cause serious harm to the fetus and newborn if taken during the second and third trimesters of pregnancy, so it must be discontinued immediately upon confirmation of pregnancy. It should not be administered to individuals who are allergic to this medication, pregnant or nursing women, or women of childbearing age who are not using appropriate contraception. It is not safe to use this medication in patients with severely impaired renal function, those undergoing renal dialysis, patients with severe liver dysfunction, or those with bile duct obstruction. Patients with muscle issues or a history of myopathy should avoid using this medication, especially at high doses, as the risk of muscle-related side effects increases. This medication contains lactose, so it should not be taken by those with lactose intolerance or related genetic conditions. Patients with very low blood pressure or reduced blood volume may experience hypotensive symptoms upon initial dosing, so caution is needed, and appropriate treatment and observation are required in such cases. Changes in kidney function may occur, so patients with impaired renal function should have regular blood tests. There is a risk of hyperkalemia, so serum potassium levels should be checked periodically. Caution is needed while driving or operating machinery due to the potential for dizziness and associated accident risks. Patients with a history of liver disease or excessive alcohol consumption should have regular liver function tests and discontinue use immediately if signs of liver damage appear. If symptoms such as myalgia, muscle weakness, or cramps occur, consult a doctor immediately, and in severe cases, discontinuation of the drug may be necessary. This medication may interact with other antihypertensive agents, diuretics, potassium-sparing diuretics, etc., so inform your doctor if you are taking any concurrent medications. Women who are pregnant or planning to become pregnant should consult their doctor before taking this medication and stop immediately upon confirmation of pregnancy. Nursing women should also exercise caution as this medication can affect the baby. Safety in children under 18 years has not been established, so it is advisable not to use it. Overdosage may result in symptoms such as hypotension and palpitations, and immediate medical attention is required. Store this medication out of reach of children and do not transfer it to another container.

Side effects

increased ALT, increased AST, increased serum creatinine, decreased creatinine clearance, headache, dizziness, sensory loss, neuropathy, drowsiness, gastroesophageal reflux disease, constipation, dental caries, dyspepsia, gastric ulcer, gastritis, gastroenteritis, musculoskeletal rigidity, atrial fibrillation, hypoglycemia, chest pain, tooth extraction, chest discomfort, peripheral edema, vertigo, abdominal pain, nausea, palpitations, hypercholesterolemia, hyperlipidemia, hyperuricemia, arthralgia, arthritis, myalgia, rash, asthenia, angioedema, anaphylactic reaction, vomiting, chronic malabsorption-like enteropathy, intestinal vascular edema, rhabdomyolysis, hyperkalemia, acute renal failure, hair loss, pruritus, urticaria, autoimmune hepatitis, including orthostatic dizziness, palpitations, hypertension, facial edema, low back pain, increased serum creatinine, diarrhea, pruritus, cough, epistaxis, upper respiratory infection, asthma, hypersensitivity reactions including angioedema, diabetes, headache, constipation, nausea, abdominal pain, pancreatitis, pruritus, rash, urticaria, myalgia, including myopathy and myositis, rhabdomyolysis, asthenia, polyneuropathy, amnesia, peripheral neuropathy, cough, dyspnea, diarrhea, thrombocytopenia, jaundice, hepatitis, increased transaminases, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms, lupus-like syndrome, muscle rupture, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders including insomnia and nightmares, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive impairment, severe myasthenia gravis, oculobulbar myasthenia gravis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to prevent air or moisture ingress and should be kept at room temperature between 1 and 30 degrees Celsius. Storing it this way will help maintain the effectiveness of the medication for a longer period.

Appearance and packaging

Appearance

White or light yellow, round film-coated tablets

Package unit

30 tablets/box [(10 tablets/Alu-Alu)×3]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.